153.08 USD
-2.20
1.42%
At close Feb 7, 4:00 PM EST
After hours
153.08
+0.00
0.00%
1 day
-1.42%
5 days
-1.00%
1 month
-2.25%
3 months
9.87%
6 months
32.05%
Year to date
2.27%
1 year
62.33%
5 years
140.88%
10 years
390.33%
 

About: Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Employees: 907

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

162% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 21

39% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 90

20% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]

11% more funds holding

Funds holding: 283 [Q2] → 313 (+30) [Q3]

7% more capital invested

Capital invested by funds: $6.66B [Q2] → $7.13B (+$473M) [Q3]

3.03% less ownership

Funds ownership: 111.72% [Q2] → 108.69% (-3.03%) [Q3]

30% less call options, than puts

Call options by funds: $19.5M | Put options by funds: $27.8M

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$120
22%
downside
Avg. target
$163
7%
upside
High target
$185
21%
upside

8 analyst ratings

positive
88%
neutral
0%
negative
13%
Piper Sandler
Matt O'Brien
63% 1-year accuracy
33 / 52 met price target
18%upside
$180
Overweight
Reiterated
27 Jan 2025
Stifel
Thomas Stephan
50% 1-year accuracy
9 / 18 met price target
14%upside
$175
Buy
Maintained
31 Dec 2024
Truist Securities
Richard Newitter
83% 1-year accuracy
34 / 41 met price target
21%upside
$185
Buy
Maintained
18 Dec 2024
Wells Fargo
Larry Biegelsen
72% 1-year accuracy
34 / 47 met price target
0%downside
$153
Overweight
Maintained
11 Dec 2024
Citigroup
Joanne Wuensch
63% 1-year accuracy
29 / 46 met price target
6%upside
$162
Buy
Upgraded
11 Dec 2024

Financial journalist opinion

Based on 4 articles about GKOS published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Neutral
Business Wire
2 weeks ago
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20.
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
Positive
Zacks Investment Research
3 weeks ago
GKOS Stock Gains Following Positive Study Data on iDose Platform
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
GKOS Stock Gains Following Positive Study Data on iDose Platform
Neutral
Business Wire
3 weeks ago
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several positive clinical updates for its iDose® sustained-release procedural pharmaceutical platform, including: In a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials, iDose TR (travoprost intracameral implant) 75 mcg, an FDA-.
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
Positive
Zacks Investment Research
1 month ago
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?
Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?
Positive
Benzinga
1 month ago
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Negative
Zacks Investment Research
1 month ago
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
GKOS announces New Drug Application submission for its Epioxa to the FDA.
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
Neutral
Business Wire
1 month ago
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a progressive, sight-threatening corneal dise.
Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
Positive
Seeking Alpha
1 month ago
Glaukos: Still Bullish, But Embedded Expectations Are Now High
Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sales, with high expectations for future growth, but a 27% margin of safety exists at current prices. GKOS's efficient asset base and strong cash conversion support sustainable growth, driven by iDose TR and iStent infinite uptake in domestic and international markets.
Glaukos: Still Bullish, But Embedded Expectations Are Now High
Charts implemented using Lightweight Charts™